AMLX vs. ANVS, VTGN, SGMT, SYRS, KPTI, RPTX, CTXR, BPTS, EBS, and IXHL
Should you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include Annovis Bio (ANVS), Vistagen Therapeutics (VTGN), Sagimet Biosciences (SGMT), Syros Pharmaceuticals (SYRS), Karyopharm Therapeutics (KPTI), Repare Therapeutics (RPTX), Citius Pharmaceuticals (CTXR), Biophytis (BPTS), Emergent BioSolutions (EBS), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical preparations" industry.
Amylyx Pharmaceuticals (NASDAQ:AMLX) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.
95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 11.8% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 38.3% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Amylyx Pharmaceuticals received 8 more outperform votes than Annovis Bio when rated by MarketBeat users. However, 94.12% of users gave Annovis Bio an outperform vote while only 63.16% of users gave Amylyx Pharmaceuticals an outperform vote.
Amylyx Pharmaceuticals currently has a consensus price target of $32.67, suggesting a potential upside of 1,637.59%. Annovis Bio has a consensus price target of $27.75, suggesting a potential upside of 117.48%. Given Amylyx Pharmaceuticals' higher possible upside, equities analysts plainly believe Amylyx Pharmaceuticals is more favorable than Annovis Bio.
Amylyx Pharmaceuticals has a beta of -0.93, indicating that its stock price is 193% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.
Amylyx Pharmaceuticals has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amylyx Pharmaceuticals has a net margin of 12.94% compared to Annovis Bio's net margin of 0.00%. Amylyx Pharmaceuticals' return on equity of 12.39% beat Annovis Bio's return on equity.
In the previous week, Amylyx Pharmaceuticals' average media sentiment score of -0.51 beat Annovis Bio's score of -0.60 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.
Summary
Amylyx Pharmaceuticals beats Annovis Bio on 11 of the 16 factors compared between the two stocks.
Get Amylyx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amylyx Pharmaceuticals Competitors List
Related Companies and Tools
